A multi-center, retrospective, preliminary observational study to assess the safety of BellaGel® after augmentation mammaplasty

Moon Seop Choi 1 · Jae Hoon Chang 2 · Chul Hwan Seul 3

Received: 20 June 2019 / Accepted: 13 January 2020 / Published online: 28 January 2020
© The Author(s) 2020

Abstract
Background BellaGel® is the only cohesive silicone gel-filled breast implant from a Korean manufacturer, and it was first developed in 2005. It was approved by the CE in 2008, thus becoming the first Asian breast implant available in the EU. We conducted this study to assess the safety of BellaGel® in patients receiving augmentation mammaplasty.

Methods We evaluated a consecutive series of 239 patients (478 breasts) who received esthetic augmentation mammaplasty using the BellaGel® (round smooth, round textured, round nanotextured, and anatomical textured types of implant) (HansBiomed Co. Ltd., Seoul, Korea) at three clinics in Korea (JW Plastic Surgery Center, BS The Body Plastic Surgery Clinic and Grace Plastic Surgery Clinic) during a period from December 1, 2015 to January 31, 2018.

Results A total of 239 patients with a mean age of 33.1 ± 8.5 years old were followed up during a mean period of 399.58 ± 232.71 days, where there were no cases of capsular contracture in our clinical series of the patients. Other complications include one case (0.4%) of seroma, three cases (1.3%) of hematoma, and one case (0.4%) of infection. Moreover, there were no significant differences in the cumulative incidences of complications between the four types of the BellaGel® ($\chi^2 = 2.322, df = 3, P = 0.508$). Furthermore, the cumulative Kaplan-Meier survival rate was estimated at 0.979 (95% CI 0.961–0.997).

Conclusions Our results indicate that the BellaGel® is such a safe breast implant that surgeons might consider using it for esthetic augmentation mammaplasty.

Level of evidence: Level III, risk/prognostic study.

Keywords Breast · Breast implants · Augmentation mammaplasty · Safety

Introduction
A silicone gel-filled breast implant was first introduced by Cronin and Gerow in 1963. Since then, there has been an evolution in implant manufacturing up to present [1, 2]. That is, the second-generation silicone gel-filled breast implants are equipped with a low viscosity gel covered with a thin, slightly permeable shell; their gel is vulnerable to leakage into the adjacent tissue if they are ruptured. The third-generation silicone gel-filled breast implants containing a cohesive gel are characterized by a decrease in occurrence of gel leakage. This is followed by the development of the fourth-generation silicone gel-filled breast implants; their advantages include a high viscosity of gel arising from an increased silicone cross-linking. Finally, the fifth-generation silicone gel-filled breast implants are characterized by a more cohesive, form-stable gel [2–5].

With technological advancements in the manufacturing of a silicone gel-filled breast implant, its safety has been scrutinized worldwide [6]. But controversial opinions exist regarding the safety of a silicone gel-filled breast implant; it eventually resulted in a moratorium of breast implants in the USA from 1992 to 2000 [7]. Since then, manufacturers of a silicone gel-filled breast implant were mandated to submit both pre-market approval (PMA) safety data and efficacy data obtained from a large-scale prospective “Core” study [8–10].

Cohesive silicone gel-filled breast implants are characterized by a high degree of softness [11, 12]. Their clinical use was approved by the Korean Ministry of Food and Drug Safety (KMFDS) in 2007. Since then, diverse brands of cohesive silicone gel-filled breast implants have become commercially

Chul Hwan Seul
pschseul@hanmail.net

1 Grace Plastic Surgery Clinic, Seoul, Korea
2 BS The BODY Plastic Surgery Clinic, Busan, Korea
3 JW Plastic Surgery Center, 6F JW Plastic Surgery Building, 553 Samsung-ro, Gangnam-gu, Seoul 06155, Korea
available in Korea. Of these, the BellaGel® (HansBiomed Co. Ltd., Seoul, Korea) is the only cohesive silicone gel-filled breast implant from a Korean manufacturer, and it was first developed in 2005. It was approved by the CE in 2008, thus becoming the first Asian breast implant available in the EU. Moreover, its clinical use was also approved by the KMFDS. Currently, diverse types of the BellaGel® implants (round smooth, round textured, round nanotextured, and anatomical textured ones) are available in 30 countries worldwide. According to a recent prospective cohort study, the BellaGel® was found to be an effective, safe implant [13].

Given the above background, we conducted this multi-center, retrospective, preliminary observational study to compare the short-term safety between the four types of the BellaGel® implants in Korean women.

**Patients and methods**

**Study patients and setting**

Between December 1, 2015 and January 31, 2018, a consecutive series of 239 patients (478 breasts) underwent esthetic augmentation mammoplasty using the BellaGel® implants at three clinics in Korea (JW Plastic Surgery Center, BS The Body Plastic Surgery Clinic and Grace Plastic Surgery Clinic). We evaluated the patients with available medical records. But we excluded the patients with a follow-up period of < 6 months. The current study was conducted in compliance with the relevant ethics guidelines. But informed consent was waived due to its retrospective nature.

**Criteria for evaluating the patients**

In the current study, we performed a retrospective review of medical records. Thus, we evaluated baseline characteristics of the patients; these include age, sex, round of surgery, smoking history, body mass index (BMI), the shape (round and anatomical shape), surface texture (smooth, textured and nanotextured surface) and volume (< 200, 200–249, 250–299, 300–349, 350–399, and ≥ 400 cc) of breast implant, the type of implant pocket, the type of surgical incision, and the method of pocket irrigation.

The patients were evaluated for the safety of augmentation mammoplasty using the BellaGel®. We compared cumulative incidences of postoperative complications between the four types of the BellaGel® (round smooth, round textured, round nanotextured, and anatomical textured implants). Moreover, we estimated cumulative survival depending on the types of the BellaGel® implants. Differences in cumulative incidences of postoperative complications between the four types of the BellaGel® served as primary safety outcome measure. Differences in cumulative survival between the four types of the BellaGel® served as secondary safety outcome measure.

**Statistical analysis of the patient data**

Data was expressed as the number of the patients with percentage, mean ± standard deviation or mean ± standard error, where appropriate. Both primary and secondary outcome measures were analyzed using the repeated measures analysis of variance (ANOVA) and Duncan’s post hoc analysis. The cumulative overall survival rate was estimated using the

| Table 1 Baseline characteristics of the patients |
|-----------------------------------------------|
| Variables                                     | Values |
| Age (years)                                   | 33.1 ± 8.5 |
| Sex (male-to-female ratio)                    | 0:239 |
| Round of surgery                              |                             |
| Primary augmentation mammoplasty              | 223 (93.3%) |
| Revision augmentation mammoplasty             | 16 (6.7%)  |
| Smoking history                               |                             |
| Never smokers                                 | 203 (84.9%) |
| Former smokers                                | 16 (6.7%)  |
| Current smokers                               | 20 (8.4%)  |
| BMI (kg/m²)                                   |                             |
| Lower body weight (< 18.5)                    | 75 (31.4%) |
| Normal body weight (18.5–24.9)                | 162 (67.8%) |
| Overweight (25–29.9)                          | 2 (0.8%)  |
| Obesity (> 30)                                | 0 (0.0%)  |
| Type of breast implant                        |                             |
| Round smooth type                             | 1 (0.4%)  |
| Round textured type                           | 18 (7.5%)  |
| Round nanotextured type                       | 118 (49.4%) |
| Anatomical textured type                      | 102 (42.7%) |
| Volume of breast implant (cc)                 |                             |
| < 200                                         | 0 (0.0%)  |
| 200–249                                       | 10 (4.2%)  |
| 250–299                                       | 85 (35.6%) |
| 300–349                                       | 130 (54.4%) |
| 350–399                                       | 13 (5.4%)  |
| ≥ 400                                        | 1 (0.4%)  |
| Implant pocket                                |                             |
| Subpectoral                                   | 1 (0.4%)  |
| Subglandular                                  | 0 (0.0%)  |
| Dual-plane                                    | 238 (99.6%) |
| Surgical incision                             |                             |
| Axillary                                      | 39 (16.3%) |
| Inframammary fold                             | 195 (81.6%) |
| Periareolar                                   | 2 (0.8%)  |
| Others                                        | 3 (1.3%)  |
| Method of pocket irrigation                   |                             |
| Saline + betadine                             | 94 (39.3%) |
| Saline + betadine + antibiotics               | 77 (32.2%) |
| Antibiotics                                   | 68 (28.5%) |
Kaplan-Meier method, for which 95% confidence intervals (CIs) were provided. Statistical analysis of the patient data was performed using the SPSS ver. 26.0 for windows (SPSS Inc., Chicago, IL). Statistical significance was set at $P < 0.05$.

## Results

### Baseline characteristics of the patients

A total of 239 patients ($n = 239$; 478 breasts) were evaluated in the current study, all of whom were women with a mean age of $33.1 \pm 8.5$ years old. They were followed up during a mean period of $399.58 \pm 232.71$ days. Their baseline characteristics are represented in Table 1.

Our clinical series of the patients include 223 cases (93.3%) of primary augmentation mammaplasty and 16 cases (6.7%) of revision one. Causes of revision augmentation mammaplasty include postoperative complications ($n = 7, 43.8\%$), dissatisfaction with the shape ($n = 7, 43.8\%$), that with the softness ($n = 1, 6.2\%$), and that with the size ($n = 1, 6.2\%$).

The patients underwent augmentation mammaplasty using a round nanotextured implant ($n = 118, 49.4\%$), an anatomical textured one ($n = 102, 42.7\%$), a round textured one ($n = 18, 7.5\%$), or a round smooth one ($n = 1, 0.4\%$). Distribution of the BellaGel® implants is shown in Fig. 1.

### Safety outcomes

Overall, there were five cases (2.1%) of complications in our series; these include three cases (1.3%) of hematoma, one case (0.4%) of infection, and one case (0.4%) of seroma. By the type of the BellaGel® implants, the incidence of postoperative complications is summarized in Table 2.

In our series, complications occurred at 7, 13, 16, 21, and 35 days postoperatively, based on which the overall survival was estimated at $0.979 \pm 0.009$ (95% CI 0.961–0.997) (Table 3).

As shown in Table 4, there were no significant differences in the cumulative survival between the four types of the BellaGel® ($\chi^2 = 2.322, df = 3, P = 0.508$).

#### Table 2  Complications depending on the type of the BellaGel®

| Variables          | Values |
|--------------------|--------|
|                    | Round smooth type ($n = 1$) | Round textured type ($n = 18$) | Round nanotextured type ($n = 118$) | Anatomical textured type ($n = 102$) |
| Hematoma           | 1      | 0      | 0      | 2      |
| Infection          | 0      | 1      | 0      | 0      |
| Seroma             | 0      | 0      | 0      | 1      |
| Capsular contracture| 0     | 0      | 0      | 0      |
Discussion

Numerous options are available for use of a breast implant in plastic surgery settings, such as augmentation mammoplasty, revision surgery, and breast reconstruction, and they include shape, size, the type and properties of gel material, fill ratio, and surface texture of shell. Esthetic outcomes and safety of surgery as well as performance of a breast implant may depend on such options [14, 15]. Multiple factors are closely associated with selection of a breast implant; these include breast anatomy and tissue measurements, a surgeon’s experience, specific application of surgery, and preference of a patient and a surgeon [16–18]. Although contemporary surgeons emphasize the importance of the shape and fill material of a breast implant in deciding on it, they should also consider other physical properties [14].

Since breast implants are placed in a human body, their safety should be rigorously assessed. Therefore, the FDA mandated manufacturers of a breast implant to conduct large-scale post-approval studies for the purposes of monitoring long-term safety outcomes. Such studies include approximately 100,000 patients receiving a silicone gel-filled breast implant during a follow-up period of 10 years [19]. It remains problematic; however, their database has yet to be completely analyzed. The currently available database has been derived from industry-sponsored studies [19–23]. Of these, relatively smaller-scale “Core” studies have been analyzed [19, 20, 22–24]. Our results are of significance in that the BellaGel® is the only cohesive silicone gel-filled breast implant whose safety has been assessed in Korea. Recently, its nanotextured type (BellaGel SmoothFine®) was released; it is advantageous in lowering capsular contracture (CC) rates and providing more softness. These properties might arise from the surface interaction that can decrease macrophage activities and enhance the elasticity of the gel [25].

Of the most common complications of augmentation mammoplasty, CC is a pathologic hardening and tightening of the capsule around the implant. Still, little is known about its exact etiologic and pathophysiologic mechanisms, for which various hypotheses have been proposed [26–28].

Previous published studies have shown that the incidence of CC is relatively lower in patients undergoing augmentation mammoplasty using textured implants [29, 30]. But this remains controversial; the use of smooth implants has also been advocated based on reports that there is no significant difference in the incidence of CC between the textured and smooth types [31–34]. Textured implants are characterized by an ability to modify the host response to wound healing. Tissue ingrowth may not only stabilize the interface of implants but also increase compatibility. This leads to an inhibition of the formation of CC [35]. In more detail, irregular surface properties of textured implants promote the growth of fibroblasts into and around their interface. The resulting contact inhibition effect may lead to the formation of a thinner capsule around the implant [36, 37]. By contrast, smooth implants promote the fibrosis characterized by the deposition of collagen fibrils in a capsule composed of the connective tissue around the implant [38, 39]. Of note, we found no cases of CC in our series. Presumably, this might be not only because we used anatomical textured or round nanotextured implants in 92% of total cases but also because we followed up our clinical series of the patients for relatively shorter periods of time. Therefore, there is a possibility that the number of cases of CC might rise over time. Indeed, a previous experimental research using the BellaGel® nanotextured implant showed that there were significant decreases in the thickness of capsule as well as collagen density with inhibition of transforming growth factor (TGF)-β-induced fibrosis [40].

In addition to the formation of CC, patients undergoing augmentation mammoplasty using prosthetic implants are also vulnerable to other complications, such as infection, hematoma, seroma, rupture, malposition, and rippling deformity [41, 42]. In the current study, our clinical series of the patients exhibited one case (0.4%) of seroma, three cases (1.3%) of hematoma, and one case (0.4%) of infection.

Our results cannot be generalized not only because we followed up our clinical series of the patients for relatively short periods of time but also because we conducted the current study at three local clinics only. The possibility of selection bias could not therefore be completely ruled out.

### Table 3 Cumulative survival at time points of follow-up

| Time point of FU | N  | n  | SR   | SE  | 95% CI         |
|------------------|----|----|------|-----|---------------|
| At 7 days        | 239| 1  | 0.996| 0.004| 0.988–1.000  |
| At 13 days       | 238| 1  | 0.992| 0.006| 0.980–1.000  |
| At 16 days       | 237| 1  | 0.987| 0.007| 0.973–1.000  |
| At 21 days       | 236| 1  | 0.983| 0.008| 0.967–1.000  |
| At 35 days       | 235| 1  | 0.979| 0.009| 0.961–0.997  |

FU, follow-up; N, number of total cases; n, incidence of postoperative complications; SR, survival rate; SE, standard error; CI, confidence interval

### Table 4 Cumulative survival depending on the type of the BellaGel®

| Type of breast implant               | N  | n  | Censored values |
|--------------------------------------|----|----|-----------------|
| Round smooth type                    | 1  | 0  | 1 (100.0%)      |
| Round textured type                  | 18 | 1  | 17 (94.4%)      |
| Round nanotextured type              | 118| 1  | 117 (99.2%)     |
| Anatomical textured type             | 102| 3  | 99 (97.1%)      |
Conclusions

In conclusion, our results indicate that the BellaGel® is such a safe breast implant that surgeons might consider using it for augmentation mammoplasty. The current study provides the latest update on the first breast implant from the Asian manufacturer and describes its safety outcomes in Asian patients, which may differ from results obtained from Western countries. Further prospective, large-scale, multi-center studies with a long-term follow-up period are warranted to establish our results.

Compliance with ethical standards

Funding The current study was sponsored by the HansBiomed Co. Ltd.

Conflict of interest Dr. Chul Hwan Seul is a non-executive medical director of the HansBiomed Co., Ltd. But Drs. Moon Seop Choi and Jae Hoon Chang declare that they have no conflict of interest.

Ethical approval The current study was conducted in compliance with the relevant ethics guidelines; all procedures performed in it were in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent Written informed consent was waived due to the retrospective nature of the current study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Maxwell GP, Gabriel A (2014) The evolution of breast implants. Plast Reconstr Surg 134:12S–17S
2. Barr S, Bayat A (2011) Breast implant surface development: perspectives on development and manufacture. Aesthet Surg J 31:56–67
3. Maxwell GP, Gabriel A (2017) Breast implant design. Gland Surg 6:148–153
4. Gabriel A, Maxwell GP (2015) The evolution of breast implants. Clin Plast Surg 42:399–404
5. Mempin M, Hu H, Chowdhury D, Deva A, Vickery K (2018) The A, B and C’s of silicone breast implants: anaplastic large cell lymphoma, biofilm and capsular contracture. Materials 11. Pii: E2393
6. Hillard C, Fowler JD, Barta R, Cunningham B (2017) Silicone breast implant rupture: a review. Gland Surg 6:163–168
7. Deva AK, Cuss A, Magnussen M, Cooter R (2019) The “game of implants”: a perspective on the crisis-prone history of breast implants. Aesthet Surg J 39:S55–S65
8. Kappel RM, Klunder AJH, Prijm GJM (2014) Silicon chemistry and silicone breast implants. Eur J Plast Surg 37:123–128
9. O’Shaughnessy K (2015) Evolution and update on current devices for prophylactic breast reconstruction. Gland Surg 4:97–110
10. Handel N, Cordray T, Gutierrez J, Jensen JA (2006) A long-term study of outcomes, complications, and patient satisfaction with breast implants. Plast Reconstr Surg 117:757–767 discussion 768–772
11. Jewell ML, Bengtson BP, Smither K, Nuti G, Perry T (2019) Physical properties of silicone gel breast implants. Aesthet Surg J 39:264–275
12. Panettiere P, Marchetti L, Accorsi D (2007) Soft cohesive silicone gel breast prostheses: a comparative prospective study of aesthetic results versus lower cohesivity silicone gel prostheses. J Plast Reconstr Aesthet Surg 60:482–489
13. Han J, Jeong JH, Bang SI, Heo CY (2019) BellaGel breast implant: 4-year results of a prospective cohort study. J Plast Hand Surg: 1–8
14. Hedén P, Montemurro P, Adams WP Jr, Germann G, Schefflan M, Maxwell GP (2015) Anatomical and round breast implants: how to select and indications for use. Plast Reconstr Surg 136:263–272
15. Maxwell GP, Schefflan M, Spear S, Nava MB, Hedén P (2014) Benefits and limitations of macrotextured breast implants and consensus recommendations for optimizing their effectiveness. Aesthet Surg J 34:876–881
16. Adams WP Jr, Small KH (2015) The process of breast augmentation with special focus on patient education, patient selection and implant selection. Clin Plast Surg 42:413–426
17. Hedén P, Brown MH, Luan J, Maxwell GP, Munhoz AM, Carter M (2015) Delphi study consensus recommendations: patient selection and preoperative planning measurements for Natrelle 410. Plast Reconstr Surg Glob Open 3:e556
18. Mallucci P, Branford OA (2016) Design for natural breast augmentation: the ICE principle. Plast Reconstr Surg 137:1728–1737
19. Coroneos CJ, Selber JC, Offodile AC 2nd, Butler CE, Clemens MW (2019) US FDA breast implant postapproval studies: long-term outcomes in 99,993 patients. Ann Surg 269:30–36
20. Hammond DC, Migliorini MM, Caplin DA, Garcia ME, Phillips CA (2012) Mentor contour profile gel implants: clinical outcomes at 6 years. Plast Reconstr Surg 129:1381–1391
21. Singh N, Picha GJ, Hardas B, Schumacher A, Murphy DK (2017) Five-year safety data for more than 55,000 subjects following breast implantation: comparison of rare adverse event rates with silicone implants versus national norms and saline implants. Plast Reconstr Surg 140:666–679
22. Speak SL, Murphy DK; Allergan Silicone Breast Implant U.S. Core Clinical Study Group (2014) Natrelle round silicone breast implants: core study results at 10 years. Plast Reconstr Surg 133: 1354–1361
23. Maxwell GP, Van Natta BW, Bengtson BP, Murphy DK (2015) Ten-year results from the natrelle 410 anatomical form-stable silicone breast implant core study. Aesthet Surg J 35:145–155
24. Calobreac MB, Schwartz MR, Zeidler KR, Pittman TA, Cohen R, Stevens WG (2017) Long-term safety of textured and smooth breast implants. Aesthet Surg J 38:38–48
25. Headon H, Kasem A, Mokbel K (2015) Capsular contracture after breast augmentation: an update for clinical practice. Arch Plast Surg 42:532–543
26. Steiert AE, Boyce M, Sorg H (2013) Capsular contracture by silicone breast implants: possible causes, biocompatibility, and prophylactic strategies. Med Devices 6:211–218
27. Huang CK, Handel N (2010) Effects of Singulair (montelukast) treatment for capsular contracture. Aesthet Surg J 30:404–408
28. Bachour Y, Bargon CA, de Blok CJM, Ket JCF, Ritt MJPF, Niessen FB (2018) Risk factors for developing capsular contracture in women after breast implant surgery: a systematic review of the literature. J Plast Reconstr Aesthet Surg 71:e29–e48
29. Spear SL, Elmaraghy M, Hess C (2000) Textured-surface saline-filled silicone breast implants for augmentation mammoplasty. Plast Reconstr Surg 105:1542–1552
30. Pollock H (1993) Breast capsular contracture: a retrospective study of textured versus smooth silicone implants. Plast Reconstr Surg 91:404–407
31. Biggs TM, Yarish RS (1990) Augmentation mammoplasty: a comparative analysis. Plast Reconstr Surg 85:368–372
32. Handel N, Jensen JA, Black Q, Waisman JR, Silverstein MJ (1995) The fate of breast implants: a critical analysis of complications and outcomes. Plast Reconstr Surg 96:1521–1533
33. Becker H, Springer R (1999) Prevention of capsular contracture. Plast Reconstr Surg 103:1766–1768
34. Fagrell D, Berggren A, Tarpila E (2001) Capsular contracture around saline-filled fine textured and smooth mammary implants: a prospective 7.5-year follow-up. Plast Reconstr Surg 108:2108–2112
35. Bergmann PA, Tamouridis G, Lohmeyer JA, Mauss KL, Becker B, Knobloch J, Mailänder P, Siemers F (2014) The effect of a bacterial contamination on the formation of capsular contracture with polyurethane breast implants in comparison with textured silicone implants: an animal study. J Plast Reconstr Aesthet Surg 67:1364–1370
36. Lei ZY, Liu T, Li WJ, Shi XH, Fan DL (2016) Biofunctionalization of silicone rubber with microgroove-patterned surface and carbon-ion implantation to enhance biocompatibility and reduce capsule formation. Int J Nanomedicine 11:5563–5572
37. Minami E, Koh IH, Ferreira JC, Wainwright AF, Chiffetti V, Rosewich TF, Pereira MD, Saldana PH, de Figueiredo LF (2006) The composition and behavior of capsules around smooth and textured breast implants in pigs. Plast Reconstr Surg 118:874–884
38. Moyer KE, Ehrlich HP (2015) Capsular contracture after breast reconstruction: collagen fiber orientation and organization. Plast Reconstr Surg 131:680–685
39. Spano A, Palmieri B, Taidelli TP, Nava MB (2008) Reduction of capsular thickness around silicone breast implants by zafirlukast in rats. Eur Surg Res 41:8–14
40. Park S, Park M, Kim BH, Lee JE, Park HJ, Lee SH, Park CG, Kim MH, Kim R, Kim EH, Heo CY, Choy YB (2015) Acute suppression of TGF-β with local, sustained release of tranilast against the formation of fibrous capsules around silicone implants. J Control Release 200:125–137
41. Ballard TNS, Hill S, Nghiem BT, Lysikowski JR, Brandt K, Cederna PS, Kenkel JM (2019) Current trends in breast augmentation: analysis of 2011-2015 maintenance of certification (MOC) tracer data. Aesthet Surg J 39:615–623
42. McGuire P, Reisman NR, Murphy DK (2017) Risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving Natrelle 410 form-stable silicone breast implants. Plast Reconstr Surg 139:3–9

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.